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Abstract
Cardiovascular drugs impact many pathways involved in depression pathophysiology and 
treatment. However, their distinct impact on mood is underrecognized and the literature is 
conflicting. Therefore, using a very large and well-characterised sample of older adults with 
hypertension, we aimed to investigate the prevalence of depressive symptoms in users of different 
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antihypertensive classes. We analysed baseline data from 14,195 older individuals with 
hypertension enroled in a large clinical trial. Median age was 75 years. The association of 
antihypertensive use by class and depression prevalence, as measured by a validated depression 
scale, was determined using logistic regression models. Multivariable logistic models were 
implemented to account for important confounding factors. Our analyses showed a positive 
association between depressive symptoms and the use of beta blockers (BB) (OR: 1.37; 95% CI: 
1.17–1.60, p < 0.01), compared with users of other antihypertensive classes. All other classes of 
antihypertensives (including angiotensin-converting enzyme inhibitors, angiotensin-receptor 
blockers, and calcium channel blockers) were not significantly associated with depressive 
symptoms. In secondary analysis, this relationship was stronger for lipophilic (39%) and 
nonselective BB (52%) compared with hydrophilic (26%) and selective medications (31%), 
respectively. This study adds further evidence for a probable association between BB and 
depression in a large sample of older adults with hypertension and no history of cardiovascular 
disease or heart failure. These findings should regenerate interest and increase awareness of 
clinicians about the possible adverse effects of these medications in an otherwise healthy older 
population.
Introduction
Depression is highly prevalent among older adults. Following the rapid global increase in the 
population aged 60 years and older, the burden of late-life depression is expected to keep 
rising [1]. The prevalence and treatment rates of hypertension also tend to increase with age 
and hypertension is the most prevalent modifiable risk factor for cardiovascular diseases 
(CVD) in this population [2]. While the direct association of hypertension and depression is 
unclear [3], aged individuals tend to be more sensitive to medication adverse events and 
chronic conditions frequently cluster in this group, leading to multimorbidity and 
polypharmacy, with several medications potentially associated with depression as an adverse 
event [4]. Therefore, finding the best therapeutic strategies for treating hypertension in old 
age without increasing neuropsychiatric adverse events can improve clinical outcomes and 
significantly increase well being and the quality of life in this vulnerable population.
Depression is bidirectionally associated with cardiometabolic conditions and cardiovascular 
drugs impact many pathways related to depression pathophysiology [5]. Therefore, an 
important, yet underrecognized, role may exist for antihypertensive drugs in the 
development, treatment and/or prevention of mood disorders. However, studies of 
neuropsychiatric effects of these drugs have shown conflicting findings. While the some 
classes of antihypertensives, like angiotensin-converting enzyme inhibitors (ACEi) or 
angiotensin-receptor blockers (ARB), have been proposed as possible preventive or 
therapeutic strategies for depression [6, 7], others like calcium channel blockers (CCB) and 
beta blockers (BB) have been associated with an increase in depression incidence and 
prevalence [4, 8].
Hence, in this study we aim to investigate the association of different classes of 
antihypertensive medication with the presence of depressive symptoms in a very well-
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This cross-sectional study is part of a large population-based randomised controlled trial 
investigating the effects of aspirin on several endpoints in a healthy older population, the 
ASPirin in Reducing Events in the Elderly (ASPREE) [9]. ASPREE recruited a total of 
19,114 participants from Australia and the United States. Inclusion criteria were community-
dwelling men and women 70 years of age and older (US minority 65 years of age and older) 
who were willing and able to provide informed consent. Exclusion criteria included a history 
of cardiovascular event or established CVD or atrial fibrillation; dementia or a score of <78 
on the Modified Mini-Mental State examination; the presence of significant disability; a 
condition with a high current or recurrent risk of bleeding, anaemia, a condition likely to 
cause death within 5 years; the current use of other antiplatelet or antithrombotic 
medication; the current use of aspirin for secondary prevention; and severe uncontrolled 
hypertension (i.e. systolic blood pressure (SBP) of ≥180 mm Hg or a diastolic blood 
pressure (DBP) of ≥105 mm Hg). To address confounding by indication, in this study we 
excluded non-hypertensive participants (n = 4919), leaving a final sample of 14,195 (74.2%) 
hypertensive individuals. Participants were recruited mainly from primary care services, 
with general practitioners as ASPREE co-investigators. Recruitment period went from 2010 
to 2014. ASPREE recruitment strategies are described in detail elsewhere [9].
Instruments and measures
Sociodemographic questionnaires were administered at baseline, with information including 
age, education, gender, smoking status, alcohol use, living status, and self-reported presence 
and/or history of medical conditions. Participants had their height, weight (used to calculate 
body mass index—BMI), abdominal circumference, blood pressure, and heart rate 
measured. The presence of hypertension was defined as the mean of three blood pressure 
measurements performed by trained study staff using an automated blood pressure device 
with an appropriate sized cuff. A mean SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg or being on 
an antihypertensive medication defined participants as hypertensive. Blood samples were 
also collected, and the presence of diabetes was defined as an elevated fasting blood glucose 
(≥7 mmol/L) or treatment for diabetes or self-report.
Medication use
Number and type of self-reported medication use were part of the baseline questionnaire and 
participants were asked to bring in their prescribed medications or a list of these. This 
information was utilised to indicate prevalent antihypertensive use, class and number of 
concomitant medications. Control groups were users of other classes of medication (primary 
hypothesis) and non-medicated hypertensive participants. Diuretic users (no previous report 
or plausible biological mechanism for an association with depression) were included in the 
second control group alongside non-medicated hypertensive individuals (n = 4747).
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The Centre for Epidemiological Studies Depression (CES-D 10) scale was used to quantify 
the presence of depressive symptoms [10]. The CES-D 10 is a self-completed questionnaire 
that scores the severity of depressive symptoms “during the past week” on a four-point (0–3) 
scale, providing a score that ranges from 0 to 30. This instrument has shown comparable 
accuracy to the full version of the CES-D (κ = 0.97) in classifying participants with 
depressive symptoms [10]. Construct validity of the CES-D 10 showed that a single score 
was a reliable and the valid measure of depression in an older population [11]. When 
compared with a formal psychiatric diagnosis of late-life depression, the scale was shown to 
have a sensitivity of 97% and a specificity of 84% [12]. Although not a formal psychiatric 
diagnosis, the presence of minor and/or subthreshold depressive symptoms has been shown 
to significantly impact the quality of life and the prognosis in older adults [13, 14]. 
Following the previous research, a cutoff of ≥8 was defined as positive screening for the 
presence of important depressive symptoms [15]. Based on the literature, we use the term 
“clinically relevant depressive symptoms” (CRD) as synonymous of positive screening 
according to our threshold [16].
Statistical analysis
Baseline characteristics of participants according to antihypertensive use were compared 
using independent sample t-tests for continuous measures or chi-square tests for categorical 
measures. The association of antihypertensive use with dichotomised depressive symptoms 
was determined using logistic regression models and odds ratios (ORs) and 95% confidence 
intervals (CIs) are reported. Based on the prevalence of CRD in this whole population being 
<10%, we assumed that the estimated OR’s are a close approximate of the prevalence ratios 
[17].
The following analyses were specified prior to the examination of data: (1) the association of 
CRD with each drug class compared with users of other classes of medication; (2) the 
association of CRD with each class of antihypertensive medication with non-medicated 
hypertensives (and diuretic users) as controls; (3) the association of CRD with combination 
treatments and number of medications. In exploratory analyses, we investigated the 
association of CRD and BB individually and divided according to their β-receptor selectivity 
and relative lipophilicity, thought to modulate the effects of these drugs in mood symptoms 
[18].
Multivariable logistic models were implemented to account for sociodemographic factors 
associated with depression, namely gender, education, smoking, and living status. To avoid 
multicollinearity between metabolic factors, stratified analyses were performed for gender, 
age, BMI, diabetes, uncontrolled hypertension, and abdominal circumference. Subgroup 
analysis according to BP levels and antidepressant use were also included. All statistical 
tests were two-tailed, and p value of <0.05 was considered to indicate statistical significance. 
All analyses were performed in the ASPREE baseline dataset, using STATA software, 
version 15.0.
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Table 1 shows characteristics of participants according to the class of antihypertensive drug 
use. The mean age was 75 years (SD: 4.5 years). A total number of 14,195 (74.2% of 
original sample) participants were classified with hypertension and included in the analyses. 
Of those, 7922 (55.8%) were female. The prevalence of hypertension tended to increase with 
age (72% in 65–74 years old to 83% in individuals with 85 years or more) and 1802 
individuals had comorbid diabetes mellitus (12.69%) (Table 1).
Overall 1414 participants (9.9%) had a CES-D 10 score of ≥8 and were classified as having 
CRD. Depressive symptoms were more prevalent in females (n = 931; 11.7%) when 
compared with males (n = 483; 7.7%); individuals educated for 12 years or less, living alone 
or in a residential care facility, and in ethnic minorities and current smokers. Current alcohol 
use was not statistically significantly associated with depressive symptoms. Antidepressants 
were used by 1624 individuals (11.4%).
Of all individuals classified as hypertensive, 66.5% were on at least one medication for 
hypertension (excluding diuretics) (Table 1). Medicated groups did not differ significantly 
regarding mean SBP and DBP or the prevalence of uncontrolled hypertension. However, the 
non-medicated group tended to have higher mean blood pressure levels, higher percentage of 
males, more educated, younger and fitter individuals (Table 1). Conversely, BB users had a 
lower heart rate, included the largest percentage of females, living alone, severely obese and 
tended to use more concomitant medications (Table 1).
Logistic regression models (Table 2) showed a statistically significant association of BB use 
and a 46% increased prevalence of CRD when compared with other classes of medication in 
the unadjusted model. The association remained significant after adjustment for multiple 
confounders (OR: 1.37; 95% CI: 1.17–1.60, p < 0.01). In separate analysis, BB use was 
associated with increased CRD when compared with non-medicated controls, but there was 
only a trend (OR: 1.28, p = 0.08) in the adjusted models (Supplement 1).
All other classes of antihypertensive medications (i.e. ACEi, ARB, and CCB) were not 
significantly associated with the prevalence of depressive symptoms in the unadjusted and 
adjusted models (Table 2), as well as in individual drug analyses.
Combination treatment was present in 27.9% of the hypertensive population (n = 3968). Of 
all possible combinations, only the combination of ARB and BB was significantly 
associated with depressive symptoms (ARB + BB: OR 1.62, 95% CI 1.18–2.22, p < 0.01). 
All possible combined treatments were analysed. A number of participants and their 
associations with depressive symptoms in multivariate models are presented in Supplement 
2.
Association between antihypertensive use and depressive symptoms by subgroup analyses 
were performed for all medication classes, but only the ones involving BB were shown to be 
significant. BB use was associated with increased depressive symptoms in all subgroups, 
except for males, individuals with diabetes and >85 years of age, possibly because of power 
issue in those groups (Table 3).
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Exploratory analyses of BB according to lipophilicity and β-receptor selectivity were also 
performed. When grouped together, lipophilic BB were associated with a 39% increase in 
the prevalence of CRD (95% CI: 1.10–1.75; p < 0.01) versus a 26% (95% CI 1.03–1.56; p = 
0.02) increase in the hydrophilic group. When divided according to β-selectivity, selective 
BB were associated with 31% (95% CI: 1.10–1.56; p < 0.01) increased odds of CRD against 
a 52% (95% CI: 1.08–2.13; p = 0.01) increase in the non-selective group. In individual 
medication analysis, metoprolol was significantly associated with higher prevalence of CRD 
and there was a trend for this association for propranolol and atenolol (Table 4). Other BB 
were not analysed individually due to the small sample size (Supplement 3).
Discussion
In this cross-sectional study of a well-characterised sample of over 14,000 hypertensive 
older adults without a history of CVD or heart failure, the use of BB was significantly 
associated with an increased prevalence of depressive symptoms. The association persisted 
after controlling for important confounding factors. On secondary analyses, lipophilic and 
non-selective BB appear to be more strongly associated with increased CRD prevalence in 
comparison with hydrophilic and β1-selective medications, respectively. Other classes of 
antihypertensive treatment had no association with depressive symptoms (except when ARB 
was used in combination with a BB). These results add further evidence to the controversial 
topic of BB use and depressive symptoms in a sample of otherwise healthy older individuals 
with hypertension.
Much of the controversy regarding BB use and depression might be explained by 
heterogeneity in studies’ populations. Studies, including reviews and meta-analyses, that 
found a protective effect of BB or sno association with depressive symptoms have often 
included participants with a history of CVD, myocardial infarction or heart failure and 
distinct age groups [19–25]. In these populations, the impact of BB on improved health may 
outweigh or confound its effect on mood.
Our results are consistent with the findings of the only study conducted in a primary care 
setting of healthy (no CVD or heart failure) hypertensive older adults from the Netherlands 
(n = 573; mean age = 70) [26]. In this cross-sectional study, the use of lipophilic BB was 
significantly associated with increased prevalence of depressive symptoms after adjustment 
for multiple confounders (OR: 1.60; 95% CI: 1.08–2.36). The study had a very similar 
design, but it was underpowered to test the effects of hydrophilic BB (n = 13), included in 
the control group. This result also agrees with a prospective study of 5104 older adults from 
the Rotterdam Study, in which the use of lipophilic BB was associated with an increased risk 
of incident depression (especially in the first 3 months of use) [27]. However, this study 
included participants with established CVD and therefore is not representative of our 
population.
Several possible mechanisms have been reported to account for the possible association of 
BB and depression, including an impact of these agents on sleep [28], circadian regulation 
[29], and sympathetic-mediated feedback loops essential for energy regulation and 
emotional arousal [30, 31]. In addition, Table 1 shows that BB users tend to include more 
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females and individuals who reported living alone, factors previously associated with 
depression in this population [15]. However, the association persisted after we controlled for 
these factors in the multivariate models.
No other classes of antihypertensive drugs were associated with the reduced or increased 
prevalence of CRD. Drugs that act on the renin-agiotensin system have been associated with 
the decreased risk of hospitalisations for mood disorders [32], lower frequency of 
antidepressant consumption [33], and increased quality of life [7]. Again, heterogeneity in 
studies, especially related to age differences, might explain some of the discrepancies. 
Plasma renin activity is significantly reduced after 60 years of age, as is aldosterone, kidney 
and adrenal gland function [34, 35], probably diminishing the effects of these drugs in this 
system.
Regarding mood disorders, CCB have been mainly explored for bipolar disorder and a 
cohort study found benefits for their use as an adjunctive therapy in the treatment of 
depression and associated cognitive dysfunction [36]. On the other hand, their use as 
monotherapy for hypertension was associated with increased hospitalisation for mood 
disorders [32]. An ongoing trial of CCB focusing on mood symptoms and cognition might 
provide more evidence for this in the near future [37].
The strengths of this study include a much larger and well-characterised sample of 
community-dwelling older adults compared with previous studies, a comprehensive 
assessment of individuals, well-validated instruments for depression assessment, and a strict 
protocol of three BP measures taken by trained professionals. The exclusion of non-
hypertensive participants significantly contributes to reduce confounding by indication 
effects, although these cannot be excluded with this study design [38]. Accounting for a 
variety of confounders, including metabolic and sociodemographic factors previously 
associated with depression, in well-powered multivariable models was another advantage.
There are also some limitations. First, due to its cross-sectional design, only association, and 
not causation, can be inferred. Also, notwithstanding the fact that the CES-D 10 is a valuable 
tool for depression screening, it is not a formal diagnostic tool for depression, hence why we 
used “CRD” instead of “depression” while citing results. Nevertheless, the presence of 
subthreshold depressive symptoms significantly impacts the quality of life in old age, 
making this a reliable instrument for screening [11, 13, 14]. The duration of therapy, primary 
indication, doses and adherence to antihypertensive drugs might also interfere in their 
relationship with mood. Unfortunately, we do not have data on those. BP levels are highly 
influenced by stress and even with three measures, this is not the gold-standard, especially in 
stress-prone individuals. Another limitation comes from exclusion criteria. Since the 
ASPREE study excluded subjects with severe diseases, dementia, uncontrolled hypertension, 
and especially, individuals with a history of CVD or heart failure, these subgroups were not 
addressed in this study. BB have an important role in reducing mortality in CVD and heart 
failure [39] and do not appear to be associated with increased prevalence of depression in 
this population [19, 20]. Because our sample is composed exclusively by older adults 
without a history of CVD, extrapolation of our results to the general population must take 
that into consideration.
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This study provides further evidence for a possible association between BB use and 
increased prevalence of depressive symptoms in a large population of community-dwelling 
hypertensive older adults. The association persisted after controlling for important 
confounding factors. There was no association of other antihypertensive drug classes and the 
prevalence of depressive symptoms. Guidelines on hypertension screening and treatment, 
progressively set more sensitive for treatment and targets, should consider the possible 
neuropsychiatric adverse events of these drugs. Despite no longer being recommended as 
first-line treatment for hypertension in older individuals [2, 40, 41] these drugs remain 
highly prescribed for this indication. Medication reviews are an important part of older 
adults’ care and deprescribing efforts should be taken if medication adverse effects in mood 
are suspected. Depression is an important factor to consider while prescribing for older 
populations, requiring clinicians to balance between mental health and quality of life and 
possible gains in morbidity and mortality. Therefore, depression merits being in the mind of 
attending physicians, guideline writers and policy makers.
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What is known about the topic
• Cardiovascular drugs impact many pathways involved in the pathophysiology 
of depression.
• Different classes of antihypertensive medication might have either beneficial 
or deleterious effects on mood.
• Mood effects of these drugs are not well described in an older population with 
no established cardiovascular disease.
What this study adds
• These findings add further evidence for an association between beta-blockers 
and depressive symptoms in older adults treated for uncomplicated 
hypertension.
• Other classes of antihypertensive medication had no association with 
depression, suggesting a safer neuropsychiatric profile for their use in the 
treatment of hypertension in otherwise healthy older adults.
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Table 2
Examining the association between the use of antihypertensive drug class and depressive symptoms (CES-D ≥ 
8) with users of other classes and non-medicated as controls.
OR 95% confidence intervals p value
Unadjusted
 ACEi 1.07 0.94–1.22 0.27
 ARB 1.03 0.92–1.16 0.61
 CCB 1.08 0.95–1.22 0.26
 BB 1.46 1.25–1.71 <0.01
Gender adjusted
 ACEi 1.09 0.95–1.24 0.20
 ARB 0.99 0.88–1.11 0.88
 CCB 1.06 0.94–1.21 0.34
 BB 1.37 1.17–1.61 <0.001
Age and gender adjusted
 ACEi 1.09 0.95–1.24 0.20
 ARB 0.99 0.88–1.11 0.88
 CCB 1.06 0.94–1.21 0.34
 BB 1.37 1.17–1.61 <0.001
Multivariate analysis
a
 ACEi 1.08 0.95–1.23 0.24
 ARB 0.99 0.89–1.12 0.94
 CCB 1.05 0.92–1.19 0.49
 BB 1.37 1.16–1.60 <0.001
ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin-receptor blockers, CCB calcium channel blockers, BB beta blockers.
a
Accounting for gender, living status, education and smoking history (all significant at 0.05 level). Non-significant variables were excluded from 
multivariable models using a backward elimination method.
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Table 3
Subgroup analyses on the association between beta blocker use and depression accounting for age, metabolic 
conditions, uncontrolled hypertension, antidepressant use, blood pressure and heart rate levels, with users of 
other classes and non-medicated as controls.
Subgroup analysis for BB users (n) CES-D ≥ 8 MOR
a
; (95% confidence intervals); p value
Age (years)
 ≤74 (8021) 1.45 (1.18–1.79); <0.01
 75–84 (5562) 1.29 (1.00–1.66); 0.05
 85+ (609) 1.04 (0.47–2.31); 0.92
Gender
 Male (6272) 1.30 (0.94–1.79); 0.10
 Female (7920) 1.38 (1.15–1.66); <0.01
BMI (kg/m2)
 ≤25 (3251) 1.73 (1.22–2.46); <0.01
 25–30 (6226) 1.27 (0.99–1.65); 0.06
 30–35 (3263) 1.54 (1.14–2.09); <0.01
 35+ (1355) 0.87 (0.55–1.36); 0.53
Diabetes
 Yes (1790) 1.30 (0.90–1.89); 0.16
 No (12,391) 1.35 (1.14–1.62); <0.01
Antidepressant use
 Yes (1624) 1.44 (1.03–2.01); 0.03
 No (12,568) 1.33 (1.11–1.60); <0.01
Uncontrolled hypertension
b
 Yes (8986) 1.34 (1.06–1.67); 0.01
 No (5206) 1.36 (1.08–1.71); <0.01
Abdominal circumference
 Normal (6033) 1.46 (1.10–1.93); <0.01
 High (8021) 1.31 (1.08–1.59); <0.01
SBP levels (mmHg)
 ≤110 (292) 0.98 (0.42–2.26); 0.96
 111–140 (5135) 1.39 (1.10–1.75); <0.01
 141–160 (6670) 1.35 (1.03–1.78); 0.03
 >160 (2098) 1.29 (0.85–1.97); 0.22
DBP levels (mmHg)
 ≤80 (8015) 1.47 (1.20–1.79); <0.01
 81–90 (4323) 1.12 (0.80–1.57); 0.49
 91–100 (1645) 1.46 (0.87–2.44); 0.15
 >100 (212) 1.43 (0.42–4.86); 0.56
Heart rate (beats/min)
 ≤60 (2424) 1.38 (1.02–1.86); 0.03
 61–70 (4972) 1.26 (0.96–1.65); 0.09
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Subgroup analysis for BB users (n) CES-D ≥ 8 MOR
a
; (95% confidence intervals); p value
 71–90 (6117) 1.48 (1.06–2.07); 0.02
 >90 (678) 4.72 (1.52–14.7); <0.01
a
MOR model-adjusted odds ratio accounting for gender, living status, education, and smoking history (all significant at 0.05 level). Non-significant 
variables were excluded from multivariable models using a backward elimination method.
b
Defined as mean blood pressure (BP) of three measurements with systolic BP > 140 mmHg; and/or diastolic BP > 90 mmHg.
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Table 4
Examining the association of BB and depressive symptoms (CES-D ≥ 8), according to medication properties, 





 and 95% CI p value
Lipophilic BB (650) 1.39; 1.10–1.75 <0.01
Hydrophilic BB (846) 1.26; 1.03–1.56 0.02
β1-selective (1276) 1.31; 1.10–1.56 <0.01
Non-selective (276) 1.52; 1.08–2.13 0.01
Propranolol (144) 1.56; 0.99–2.48 0.05
Metoprolol (434) 1.40; 1.06–1.84 0.01
Atenolol (794) 1.21; 0.98–1.51 0.07
a
BB’s were classified in subgroups according to properties following Poirier, 2014 [18] as follows:
Lipophilic BB’s: (i.e. pindolol, propranolol, timolol, and metoprolol)
Hydrophilic BB’s: (i.e. atenolol, carteolol, nadolol, sotalol, and labetalol)
Selective BB: (i.e. atenolol, bisoprolol, labetalol, metoproplol, and nebivolol)
N selective BB: (i.e. propranolol, carvedilol, nadolol, timolol, pindolol, and sotalol).
b
Accounting for gender, living status, education, and smoking history (all significant at 0.05 level). Non-significant variables were excluded from 
multivariable models using a backward elimination method.
J Hum Hypertens. Author manuscript; available in PMC 2020 November 14.
